Cerivastatin and gemfibrozil. A case of severe rhabdomyolysis;Rabdomiólisis grave asociada a cerivastatina y gemfibrozilo

Medicina Clinica

Volumn 117, Issue 7, 2001, Pages 278-279

  De Arriba Mendez J J ^a   Merino, E G ^a   Barcelona, J A S ^a   Mendez L S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; ENALAPRIL; FLUOXETINE; GEMFIBROZIL; LACIDIPINE; OMEPRAZOLE; PLACEBO;

ADULT; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LETTER; RHABDOMYOLYSIS;

EID: 0008694825     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)72086-6     Document Type: Letter

References (10)

1. Cerivastatin. A review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia
2. Adverse drug reactions advisory committee (ADRAC). Cerivastatin and rhabdomyolysis-avoid gemfibrozil
3. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
4. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil
5. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
6. A case with severe rhabdomyolysis and renal failure associated with cerivastatingemfibrozil combination therapy. A case report
7. HMG-CoA reductase inhibitors and myotoxicity
8. Comparative tolerability of the HMG-CoA reductase inhibitors
9. Drug treatment of lipid disorders
10. Medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis